December 10, 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year - Biotech TV - MaaT Pharma

To see the interview, click here!

Previous PostReplay: KOL insights and MaaT013 Data from ASH 2024 Meeting
Next PostDecember 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club